Back grey_arrow_rt.gif
 
 
Egrifta (Tesamorelin) is Available
 
 
  pdf Prescribing Information attached
January 21, 2011
 
Download the PDF here
 
EMD Serono, Inc. is proud to announce the full commercial availability of EGRIFTATM (tesamorelin for injection). We are pleased to provide the full Prescribing Information for EGRIFTA including Patient Information and Patient Instructions for Use. The Prescribing Information has key information about EGRIFTA, including its full indication and limitations, clinical data and safety information. EMD Serono is committed to ensuring that appropriate patients have access to EGRIFTATM. To make this commitment a reality, the following programs and services are now available to support patients in gaining access to and staying on EGRIFTATM.
 
The AXIS Center
 
The AXIS Center offers dedicated reimbursement, teaching and adherence support for patients on EGRIFTATM. With a team of dedicated Reimbursement Case Managers, the AXIS Center assists patients throughout the process of getting access to and staying on EGRIFTATM.
 
The AXIS Center offers in-home or in-office injection training to every new patient through a national network of Injection Trainers. Every new patient also receives an Education Kit that provides video and print administration guides along with other useful tools. Support continues throughout treatment with product support specialists available 24 hours-a-day/7 days-a-week to answer patients' questions about mixing and injecting EGRIFTATM.
 
To start the process, licensed healthcare providers must fax a Statement of Medical Necessity (SMN) (i.e., prescription), signed by the healthcare provider, and Patient Authorization, signed by the patient, to the AXIS Center at 866-823-9554. SMNs will be provided by the EMD Serono sales team or can be requested by calling the AXIS Center at 877-714-AXIS (2947).
 
Co-pay Assistance Program
 
For commercially insured patients with a prescription drug benefit that covers EGRIFTATM, the Co-pay Assistance Program covers up to $2,400 of patients' out of pocket cost over a 12-month period. Patients must use the card for the first time in 2011 and can off-set up to $200 of their copay or coinsurance for up to 12 uses prior to 12/31/12, not more than once every 21 days. Patients may not use the Co-pay Assistance Program if they receive drug benefits from state or federal health care initiatives (including Medicare or Medicaid). This program is not valid in the Commonwealth of Massachusetts.
 
Patient Assistance Program (PAP)
 
The PAP program provides free EGRIFTATM for eligible patients who are uninsured or under-insured. Patients must meet other eligibility requirements, including a household income that does not exceed 600% of the Federal Poverty Level (FPL). Patients must also have a diagnosis of the indicated condition and be a resident of the United States. The EGRIFTA PAP program provides free drug for one year and patients will need to reapply if they seek to continue receiving EGRIFTATM. The EGRIFTATM PAP program is coordinated by the AXIS Center at 877-714-AXIS (2947). We are excited to be launching EGRIFTATM with a comprehensive set of patient support programs. Our aim is to offer the most relevant programs for patients, so, as always, please provide us with any feedback that you may have.
 
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org